Navigation Links
LSU receives $15 million grant from NIH to build biomedical research pipeline for Louisiana
Date:9/27/2010

in the state, including Louisiana Tech University, LSU-Shreveport, Southern University, the University of Louisiana at Monroe and Xavier University.

Researchers and students at these schools are paired with mentors and collaborators at the state's biomedical research intensive centers, including LSU, LSU Health Sciences Centers in Shreveport and New Orleans, Pennington Biomedical Research Center, the Tulane Medical Center and the Tulane National Primate Research Center. The program also includes an extensive summer research training program from undergraduates and includes students from 23 undergraduate institutions in the state.


'/>"/>

Contact: Ginger Guttner
gguttner@vetmed.lsu.edu
225-578-9922
Louisiana State University
Source:Eurekalert

Page: 1 2

Related biology news :

1. Wistar Institute researcher receives New Innovator award from NIH
2. L-1 Identity Solutions Receives $5.9 Million Drivers License Contract Expansion from the State of Mississippi
3. Kount Receives Patent for Device Fingerprinting
4. American College of Medical Genetics receives $13.5M NIH contract
5. Penn State receives new NASA astrobiology grant
6. Global Viral Forecasting Initiative receives $11M to implement pandemic early warning system
7. Vidaza receives positve opinion from European CHMP
8. Case Western Reserve receives Ellison Medical Foundation New Scholar in Aging award
9. Montana State partnership receives $66.9M for carbon sequestration
10. Oklahoma EPSCoR receives $20 million for biofuels research
11. UC Riverside rice geneticist receives high honor from US Department of Agriculture
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/21/2015)... , July 21, 2015  NXT-ID, Inc. (NASDAQ: ... biometric authentication company focused on the growing mobile ... wallet, announces that it has filed provisional patent ... Method. This invention highlights next ... authorizes an account, but also the user using ...
(Date:7/9/2015)... July 9, 2015  Synaptics Inc. (NASDAQ: SYNA ), ... that it will report financial results for the fourth ... 2015 after the close of market. The company will ... at 2:00 p.m. PT (5:00 p.m. ET), during which ... participate on the live call, analysts and investors should ...
(Date:7/8/2015)... FRANKLIN LAKES , N.J. and NEW YORK ... and Company) and Guidepoint today announced ... selected start-up healthcare companies with free access to Guidepoint,s ... mentoring several start-ups that are developing cutting-edge technologies to ... of a dedicated Guidepoint research manager, each start-up entrepreneur ...
Breaking Biology News(10 mins):NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 2NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 3NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 4Synaptics to Report Fourth Quarter, Fiscal Year 2015 Results on July 30 2BD and Guidepoint Team to Connect Healthcare Start-up Companies With Business and Scientific Experts 2BD and Guidepoint Team to Connect Healthcare Start-up Companies With Business and Scientific Experts 3
... on the Cohen Y chromosome indicates the Jewish priesthood, the ... a single male lineage dating to ancient Hebrew times. ... Jewish priesthood that traced its patrilineal dynasty and seemed to ... (and brother of Moses), was one of a number of ...
... A scientist at the La Jolla Institute for Allergy & ... (NIH),s top awards -- the 2009 NIH Director,s Pioneer Award. ... costs of up to $4.7 million over five years, and ... whose novel proposals offer the potential to make extraordinary contributions ...
... RICHLAND, Wash. -- An analytical chemist at the Department ... with a National Institutes of Health Director,s New Innovator ... make new research and clinical diagnostic tools that are ... The award, which comes with a $1.5 million, ...
Cached Biology News:New genetic research indicates Jewish priesthood has multiple lineages 2Visionary concept earns La Jolla Institute scientist prestigious NIH Pioneer Award 2Visionary concept earns La Jolla Institute scientist prestigious NIH Pioneer Award 3Visionary concept earns La Jolla Institute scientist prestigious NIH Pioneer Award 4PNNL chemist earns NIH New Innovator Award 2PNNL chemist earns NIH New Innovator Award 3
(Date:7/28/2015)... YORK , July 28, 2015 Tauriga ... a diversified life sciences company, today announced that its ... shares of common stock of the Company from 1,000,000,000 ... on July 27, 2015 at the Law Offices of ...  At the Special Meeting, there were 480,655,929 shares of ...
(Date:7/28/2015)... , July 28, 2015  Moerae Matrix ... Phase 1 clinical trial with MMI-0100, a first-in-class ... being developed for pulmonary disorders characterized by inflammation ... United Kingdom , is a double-blind, ... evaluating the safety and tolerability of MMI-0100 when ...
(Date:7/28/2015)... , July 28, 2015 CSL ... Drug Administration has accepted for review the company,s Biologics ... VIII single-chain (rVIII-SingleChain) for the treatment of hemophilia A. ... endpoints. Hemophilia A is ... factor VIII; nearly all affected patients are male. People ...
(Date:7/28/2015)... Md. and RESEARCH TRIANGLE PARK, N.C., July 28, 2015 ... today announced its financial results for the second ...  sales grew nearly 300% as compared to the ... first launched," said Roger Jeffs, Ph.D., United Therapeutics, ... Orenitram sales was due to an increase in ...
Breaking Biology Technology:Tauriga Sciences, Inc. Stockholders Approve Increase In Authorized Common Stock 2Tauriga Sciences, Inc. Stockholders Approve Increase In Authorized Common Stock 3Moerae Initiates Lipopolysaccharide (LPS) Challenge Study of Inhaled MMI-0100 for Pulmonary Disease Following Encouraging Safety and Tolerability Observed in Single Ascending Dose Phase 1 Study 2U.S. FDA Accepts for Review CSL Behring's Biologics License Application for Its Novel rVIII-SingleChain Therapy for Patients with Hemophilia A 2U.S. FDA Accepts for Review CSL Behring's Biologics License Application for Its Novel rVIII-SingleChain Therapy for Patients with Hemophilia A 3United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 2United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 3United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 4United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 5United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 6United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 7United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 8United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 9United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 10United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 11
... , , ... AB (publ),and BioChromix AB announced today the formation of BioChromix Pharma ... its unique,knowledge of molecular chemistry. Karolinska Development will initially take,28 percent ... are very excited about BioChromix Pharma as they have a novel,approach ...
... , ... supports Higher Education and Local Youth by establishing Five College Scholarships. The first ... pursue Bio-Technology studies at NoVA. The company will also sponsor four scholarships for ... ...
... Jan. 13 Oxygen Biotherapeutics, Inc. (OTC Bulletin Board: ... the introduction of new products during a presentation today at the ... the brief presentation, limited by conference organizers to 10 minutes per ... in its cosmetics line during 2010. They include an eye cream ...
Cached Biology Technology:Karolinska Development Expands its Life Science Portfolio With BioChromix Pharma 2Karolinska Development Expands its Life Science Portfolio With BioChromix Pharma 3RiVIdium Inc. Creates Five Local Scholarships 2Oxygen Biotherapeutics, Inc. Outlines Plans for New Products During Investor Conference Presentation 2Oxygen Biotherapeutics, Inc. Outlines Plans for New Products During Investor Conference Presentation 3
Glycerokinase; from Bacillus stearothermophilus...
...
...
... safety cabinets Heraeus HERAsafe KS convince with an ... ,The new frameless slanted window does not obscure ... front window design makes it easy to work ... with a height of more than 250 mm ...
Biology Products: